title: Percutaneous Doxycycline Treatment of Juxtaphyseal Aneurysmal Bone Cysts.
abstract: BACKGROUND
  A recurrence rate of 19% to 23% has been reported in juxtaphyseal aneurysmal bone cysts (ABC) without en bloc resection or amputation. No percutaneous surgical techniques or drug treatments have demonstrated consistent bone healing with normal physeal growth and a recurrence rate of <19%. Doxycycline has properties that may make it an appropriate agent for percutaneous treatment of juxtaphyseal ABC in skeletally immature patients.
  
  
  METHODS
  We retrospectively reviewed 16 patients who underwent percutaneous treatment of ABCs with doxycycline from 2006 to 2011. The mean age was 7.1 years (range, 2 to 15 y). There were 16 treatment locations: humerus (9), tibia (3), fibula (2), femur (1), and ulna (1). Sixteen patients completed treatment involving 102 treatment sessions (2 to 14 sessions per patient). Treatment response was evaluated radiographically by measuring the lytic component, thickness of involved cortex, and signs of bony remodeling, and evidence of physeal growth arrest. Recurrence was indicated by new areas of lytic destruction after completion of treatment. The minimum follow-up was 18 months (mean, 39 mo).
  
  
  RESULTS
  All 16 patients demonstrated reduction in lytic destruction, bony healing, and bony remodeling. One patient demonstrated recurrent minimal lytic destruction after 20 months of observation. Seven patients (7/16, 44%) demonstrated physeal ABC involvement; 5 of 7 patients healed with a physeal bone bridge, all ≤15% of the physeal surface area, 1 with mild central physeal deformity. All patients with focal transphyseal ABC involvement (4/4, 100%) demonstrated focal bone bridge after treatment. No patient had diffuse physeal growth arrest; only patients with intraphyseal or transphyseal ABC involvement had focal physeal growth arrest.
  
  
  CONCLUSIONS
  In this series, patients undergoing percutaneous doxycycline treatment of juxtaphyseal ABCs demonstrated ABC healing and a recurrence rate of 6% at >18 months. Patients without physeal ABC involvement demonstrated no evidence of physeal growth arrest.
authors.affiliation: Departments of *Radiology †Orthopedic Surgery, Nationwide Children's Hospital and The Ohio State University Medical Center, Columbus, OH.
authors.forename: William E
authors.initials: WE
authors.lastname: Shiels
authors.forename: Allan C
authors.initials: AC
authors.lastname: Beebe
authors.forename: Joel L
authors.initials: JL
authors.lastname: Mayerson
mesh_terms: D000293:Adolescent; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D017824:Bone Cysts, Aneurysmal / Q000000981:diagnostic imaging / Q000188:drug therapy*; D002648:Child; D002675:Child, Preschool; D004318:Doxycycline / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007267:Injections; D008297:Male; D056687:Off-Label Use; D011859:Radiography; D012008:Recurrence; D012189:Retrospective Studies
chemical_list: D020533:Angiogenesis Inhibitors; D004318:Doxycycline